202138-50-9
- Product Name：Tenofovir Disoproxil Fumarate
- Molecular Formula：C19H30N5O10P.C4H4O4
- Purity：99%
- Molecular Weight：635.522
Product Details:
CasNo： 202138-50-9
Molecular Formula： C19H30N5O10P.C4H4O4
Appearance： almost white crystalline
Buy High Quality Tenofovir Disoproxil Fumarate,Wholesale 202138-50-9 Safe Transportation
- Molecular Formula:C19H30N5O10P.C4H4O4
- Molecular Weight:635.522
- Appearance/Colour:almost white crystalline
- Vapor Pressure:2.06E-16mmHg at 25°C
- Melting Point:219oC
- Boiling Point:642.7 °C at 760 mmHg
- Flash Point:342.5 °C
- PSA：269.85000
- Density:1.45 g/cm3
- LogP:3.32860
Tenofovir disoproxil fumarate(Cas 202138-50-9) Usage
|
Overview |
Tenofovir disoproxil fumarate is an oral prodrug of tenofovir, which is an acyclic nucleoside phosphonate analogue of adenosine 5′-monophosphate. |
|
Uses |
Tenofovir disoproxil fumarate (TDF) is a prodrug of tenofovir, a potent nucleotide analogue reverse-transcriptase inhibitor primarily used in the treatment of HIV infection and chronic hepatitis B virus (HBV) infection. Tenofovir disoproxil fumarate is used in combination with other medications to treat HIV infection in adults and children 2 years of age and older. It is also indicated for the treatment of chronic hepatitis B virus (HBV) infection in adults and children aged 12 and older. |
|
Definition |
ChEBI: A fumarate salt prepared from equimolar amounts of tenofovir disoproxil and fumaric acid. It is used in combination therapy for the treatment of HIV infection. |
|
Brand name |
Viread (Gilead Sciences). |
| Safety Profile | Tenofovir disoproxil fumarate has been well tolerated in clinical trials, with durations of follow-up up to 96 weeks. It is associated with more favorable lipid profiles compared to other antiretroviral medications and has not been linked to mitochondrial toxicity observed with certain nucleoside analogs. |
InChI:InChI=1/C19H30N5O10P.C4H4O4/c1-12(2)33-18(25)28-9-31-35(27,32-10-29-19(26)34-13(3)4)11-30-14(5)6-24-8-23-15-16(20)21-7-22-17(15)24;5-3(6)1-2-4(7)8/h7-8,12-14H,6,9-11H2,1-5H3,(H2,20,21,22);1-2H,(H,5,6)(H,7,8)/b;2-1+/t14-;/m1./s1
202138-50-9 Relevant articles
METHODS FOR IMPROVING PURITY OF TENOFOVIR DISOPROXIL FUMARATE, AND COMPOSITIONS THEREOF
-
Paragraph 0189; 0197; 0199; 0201; 0203; 0205;0207, (2020/07/16)
Methods for producing tenofovir disoprox...
Tenofovir Disoproxil Fumarate Clinical Pharmacology and Pharmacokinetics
Brian P. Kearney, John F. Flaherty & Jaymin Shah
Clinical Pharmacokinetics, Volume 43, pages 595–612, (2004)
Tenofovir exhibits longer serum (17 hours) and intracellular (≥60 hours) half-lives than those of nucleoside analogues, which supports a flexible once-daily administration schedule. The pharmacokinetics of tenofovir are dose-proportional and similar in healthy volunteers and HIV-infected individuals.
The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years
Nelson, Mark Ra; Katlama, Christineb; Montaner, Julio Sc; Cooper, David Ad; Gazzard, Briana; Clotet, Bonaventurae; Lazzarin, Adrianof; Schewe, Knudg; Lange, Joeph; Wyatt, Christinai; Curtis, Suej; Chen, Shan-Shanj; Smith, Stephenj; Bischofberger, Norbertj; Rooney, James Fj for the Tenofovir DF Expanded Access Team
AIDS 21(10):p 1273-1281, June 2007.
To characterize the safety profile of tenofovir disoproxil fumarate (DF) for the treatment of HIV infection in adults over the first 4 years of use.
202138-50-9 Upstream products
-
110-17-8
(2E)-but-2-enedioic acid
-
201341-05-1
tenofovir disoproxil
-
66224-66-6
adenine
-
14047-28-0
(R)-9-(2-hydroxypropyl)adenine
202138-50-9 Downstream products
-
1432630-26-6
9-[(R)-2-[[bis[[ (isopropoxycarbonyl)oxy]methoxy]phosphinyl]-methoxy]propyl]adenine fumarate Tenofovir disoproxil fumarate
-
201341-05-1
tenofovir disoproxil
Relevant Products
-
Fosfomycin tromethamineCAS：78964-85-9
-
LacosamideCAS：175481-36-4
-
OlanzapineCAS：132539-06-1
